Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lilly’s Taltz Receives U.S. FDA Approval for Treating Active Psoriatic Arthritis

Eli Lilly and Company announced that the U.S. FDA approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA).

Read More »

Stelara shows promise against lupus in study

J&J’s blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a mid-stage clinical trial.

Read More »

AbbVie Touts Late-Stage Psoriasis Drug Trial Data

AbbVie said its Phase III drug risankizumab is more effective than its own blockbuster Humira or J&J’s Stelara in treating moderate-to-severe chronic plaque psoriasis.

Read More »

Almirall Discontinues R&D for Two Drugs in the U.S.

Almirall SA announced it plans to halt all research into P3058 (onychomycosis) and P3073 (nail psoriasis) in the U.S. However, clinical trials planned in Europe will continue as scheduled.

Read More »

European panel backs Janssen’s psoriasis drug

A European Medicines Agency panel recommended the approval of Johnson & Johnson unit Janssen’s drug guselkumab for treating plaque psoriasis in adults.

Read More »

FDA approves Cyltezo, a biosimilar to Humira

The FDA approved Boehringer Ingelheim Pharmaceuticals’ Cyltezo, a biosimilar to Humira, in a pre-filled syringe for treating chronic inflammatory diseases.

Read More »

Biosimilar version of Humira approved in Europe

A biosimilar version of AbbVie Inc.’s blockbuster arthritis drug Humira, produced by a joint venture of Biogen Inc. and Samsung Biologics, was approved by EU regulators.

Read More »

Special Feature – First Year After Launch: The specialties win again

Just like 2016 and the year before, specialty drugs dominate the 2017 list of top performers in the most recent first year after launch class.

Read More »

FDA Gives Nod to J&J’s Tremfya

FDA approved Janssen Biotech’s Tremfya (guselkumab) for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Read More »

Novartis receives EU approval for Cosentyx label update

Novartis said the Committee for Medicinal Products for Human Use approved a label update for Cosentyx (secukinumab), the first interleukin-17A approved to treat psoriasis.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom